"At Unified Health, we believe in providing our patients with exceptional medical care and access to the most advance medical technology. Our experienced team of providers are committed to delivering the highest quality of dermatological care to our patients, especially when it comes to the earliest detection possible of melanoma - the deadliest form of skin cancer. For these reasons, we are excited to use Nevisense and believe it will help us improve outcomes for our patients", says Michael Lin, MD, Board-Certified Dermatologist and Founder of Unified Health.

"SciBase and Unified Health are well aligned with a shared mission to provide clinicians with early detection of melanoma solutions that can drive improved patient outcomes", says Pia Renaudin, CEO of SciBase. "We are encouraged to see more patients getting access to our point-of-care technology that enables the earliest detection possible of melanoma when it is almost 100% curable".

For additional information, please contact:
Pia Renaudin, VD, tel. +46732069802, e-mail: pia.renaudin@scibase.com
Certified Advisor (CA):

Vator Securities

Tel: +46 8 580 065 99

Email: ca@vatorsec.se

About SciBase:

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases